Literature DB >> 14743878

Probiotics in gastroenterology: indications and future perspectives.

D Goossens1, D Jonkers, E Stobberingh, A van den Bogaard, M Russel, R Stockbrügger.   

Abstract

Nowadays. there is a growing interest in probiotics as a safe way of changing the intestinal bacterial flora. Probiotics may have potential in several gastroenterological conditions, especially when the intestinal flora has been disturbed. Most scientific evidence is available for diarrhoea patients treated with Lactobacillus GG, Lactobacillus reuteri or Saccharomyces boulardii. Meta-analyses have shown an overall reduction in the risk of antibiotic-associated diarrhoea during treatment with probiotics, and benefits have also been demonstrated for patients with rota-virus-associated diarrhoea. Patients with inflammatory bowel disease, an inflammatory disorder characterized by a change in the intestinal flora, are another important target group for which probiotics may be beneficial. It has been claimed that in ulcerative colitis and Crohn disease patients, lactobacilli, S. boulardii and Escherichia coli reduce relapses. but most studies were not placebo-controlled. A reduction in relapses has also been demonstrated in pouchitis patients treated with a multispecies probiotic. Irritable bowel syndrome might be another clinical indication for probiotic therapy, but results of clinical trials performed in these patients are inconsistent. Additionally, probiotics may improve lactose absorption. Helicobacter pylori eradication and constipation. Finally, in animal models of colorectal cancer, treatment with probiotics reduces the prevalence of this disease, and in humans the amount of genotoxic substances in faeces has been reduced. In conclusion, the results of studies on the effects of probiotics in gastrointestinal conditions are encouraging. but well-designed placebo-controlled studies are warranted before recommendations for therapeutic or preventive use can be given. Many issues still have to be resolved, including optimal dose and duration of treatment, selection of and differences between the several available probiotic strains, and, importantly, their mechanisms of actions have to be elucidated.

Entities:  

Mesh:

Year:  2003        PMID: 14743878     DOI: 10.1080/00855920310002645

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  10 in total

1.  New insights into the hygiene hypothesis in allergic diseases: mediation of sibling and birth mode effects by the gut microbiota.

Authors:  John Penders; Kerstin Gerhold; Carel Thijs; Kurt Zimmermann; Ulrich Wahn; Susanne Lau; Eckard Hamelmann
Journal:  Gut Microbes       Date:  2014-01-23

2.  The C/C-13910 genotype of adult-type hypolactasia is associated with an increased risk of colorectal cancer in the Finnish population.

Authors:  H Rasinperä; C Forsblom; N S Enattah; P Halonen; K Salo; M Victorzon; J-P Mecklin; H Järvinen; S Enholm; G Sellick; H Alazzouzi; R Houlston; J Robinson; P-H Groop; I Tomlinson; S Schwartz; L A Aaltonen; I Järvelä
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

3.  Probiotic Lactobacillus spp. diminish Helicobacter hepaticus-induced inflammatory bowel disease in interleukin-10-deficient mice.

Authors:  Jeremy A Peña; Arlin B Rogers; Zhongming Ge; Vivian Ng; Sandra Y Li; James G Fox; James Versalovic
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

4.  Clostridium butyricum TO-A culture supernatant downregulates TLR4 in human colonic epithelial cells.

Authors:  Atsushi Isono; Tatsuro Katsuno; Toru Sato; Tomoo Nakagawa; Yasutaka Kato; Naoki Sato; Gen'ichiro Seo; Yasuo Suzuki; Yasushi Saito
Journal:  Dig Dis Sci       Date:  2007-04-03       Impact factor: 3.199

5.  Saccharomyces boulardii prevents oral-poliovirus vaccine-induced IgA nephropathy in mice.

Authors:  Alper Soylu; Sema Berktaş; Sülen Sarioğlu; Güven Erbil; Osman Yilmaz; Belde K Demir; Yahya Tufan; Didem Yeşilirmak; Mehmet Türkmen; Salih Kavukçu
Journal:  Pediatr Nephrol       Date:  2008-04-30       Impact factor: 3.714

6.  The effect of Saccharomyces boulardii on human colon cells and inflammation in rats with trinitrobenzene sulfonic acid-induced colitis.

Authors:  Sang Kil Lee; Youn Wha Kim; Sung-Gil Chi; Yeong-Shil Joo; Hyo Jong Kim
Journal:  Dig Dis Sci       Date:  2008-07-10       Impact factor: 3.199

7.  Commentary: Probiotic and technological properties of Lactobacillus spp. strains from the human stomach in the search for potential candidates against gastric microbial dysbiosis.

Authors:  Amit K Tyagi; Sahdeo Prasad
Journal:  Front Microbiol       Date:  2015-05-19       Impact factor: 5.640

8.  Chemoprevention of gastrointestinal cancer: the reality and the dream.

Authors:  Kyung-Soo Chun; Eun-Hee Kim; Sooyeon Lee; Ki Baik Hahm
Journal:  Gut Liver       Date:  2013-02-07       Impact factor: 4.519

9.  Protective effect of vaginal Lactobacillus paracasei CRL 1289 against urogenital infection produced by Staphylococcus aureus in a mouse animal model.

Authors:  Gabriela Zárate; Viviana Santos; María Elena Nader-Macias
Journal:  Infect Dis Obstet Gynecol       Date:  2007-03-29

Review 10.  Prokaryotes Versus Eukaryotes: Who is Hosting Whom?

Authors:  Guillermo Tellez
Journal:  Front Vet Sci       Date:  2014-10-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.